Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 6/20 | 0.58 |
| ▸ | HPGD | P15428 | 3/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | RECQL | P46063 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.47 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | G6PD | P11413 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30916607 | 0.88 | CYP3A4 (0.71) | CYP3A4HPGDMAPK1USP2SMN1; SMN2 | |
| SCHEMBL4263528 | 0.88 | CYP3A4 (0.71) | CYP3A4HPGDMAPK1USP2SMN1; SMN2 | |
| SCHEMBL16018016 | 0.88 | CYP3A4 (0.68) | CYP3A4HPGDMAPK1USP2SMN1; SMN2 | |
| SCHEMBL2381337 | 0.85 | LMNA (0.52) | CYP3A4HPGDMAPK1USP2SMN1; SMN2 | |
| SCHEMBL484746 | 0.82 | KMT2A (0.64) | CYP3A4HPGDMAPK1SMN1; SMN2KMT2A | |
| SCHEMBL2380561 | 0.80 | MTNR1B (0.54) | SMN1; SMN2POLBLMNAKDM4E | |
| SCHEMBL7123880 | 0.80 | CYP3A4 (0.56) | CYP3A4HPGDSMN1; SMN2KMT2APOLB | |
| Hydrochloric Acid SCHEMBL939484 | 0.80 | KMT2A (0.62) | CYP3A4HPGDMAPK1SMN1; SMN2KMT2A | |
| SCHEMBL11067587 | 0.80 | CYP3A4 (0.79) | CYP3A4HPGDMAPK1KMT2APOLB | |
| SCHEMBL939482 | 0.80 | CYP3A4 (0.56) | CYP3A4HPGDMAPK1USP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11071736-B2 | Modulators of HEC1 activity and methods therefor | TAIVEX THERAPEUTICS CORPORATION | 2021-07-27 | — | — | US | disclosed |
| US-10588909-B2 | Modulators of HEC1 activity and methods therefor | TAIVEX THERAPEUTICS CORPORATION (TW) | 2020-03-17 | — | — | US | disclosed |
| EP-2785714-B1 | IMPROVED MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | TAIVEX THERAPEUTICS CORP (TW) | 2018-11-21 | — | — | EP | disclosed |
| US-20180318310-A1 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | DEVELOPMENT CENTER OF BIOTECHNOLOGY (TW) | 2018-11-08 | — | — | US | disclosed |
| US-9422275-B2 | Small molecule modifiers of the HEC1-NEK2 interaction in G2/M | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-08-23 | — | — | US | disclosed |
| US-9409902-B2 | Modulators of HEC1 activity and methods therefor | TAIVEX THERAPEUTICS CORPORATION (TW) | 2016-08-09 | — | — | US | disclosed |
| US-9273080-B2 | Metal complexes | MEREK PATENT GMBH (DE) | 2016-03-01 | — | — | US | disclosed |
| US-20150250794-A1 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | TAIVEX THERAPEUTICS CORP (TW) | 2015-09-10 | — | — | US | disclosed |
| EP-2547676-B1 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | TAIVEX THERAPEUTICS INC (TW) | 2015-07-29 | — | — | EP | disclosed |
| EP-2547676-B1 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | TAIVEX THERAPEUTICS INC (TW) | 2015-07-29 | — | — | EP | disclosed |
| EP-2785714-A1 | IMPROVED MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | Taivex Therapeutics Corporation (TW) | 2014-10-08 | — | — | EP | disclosed |
| US-20130190312-A1 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | TAIVEX THERAPEUTICS CORPORATION (TW) | 2013-07-25 | — | — | US | disclosed |
| WO-2013082324-A1 | IMPROVED MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | TAIVEX THERAPEUTICS CORPORATION (TW) | 2013-06-06 | — | — | WO | disclosed |
| US-20130082209-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2013-04-04 | — | — | US | disclosed |
| EP-2547676-A2 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | Taivex Therapeutics Inc. (TW) | 2013-01-23 | — | — | EP | disclosed |
| US-20110230486-A1 | Modulators Of HEC1 Activity And Methods Therefor | TAIVEX THERAPEUTICS CORPORATION (TW) | 2011-09-22 | — | — | US | disclosed |
| US-20110230486-A1 | Modulators Of HEC1 Activity And Methods Therefor | TAIVEX THERAPEUTICS CORPORATION (TW) | 2011-09-22 | — | — | US | disclosed |
| US-20110230486-A1 | Modulators Of HEC1 Activity And Methods Therefor | TAIVEX THERAPEUTICS CORPORATION (TW) | 2011-09-22 | — | — | US | disclosed |
| WO-2011115998-A2 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | TAIVEX THERAPEUTICS INC. (CN) | 2011-09-22 | — | — | WO | disclosed |
| WO-2011115998-A2 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | TAIVEX THERAPEUTICS INC. (CN) | 2011-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180318310-A1 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | WEE1, WEE2, NEK11 | CYP3A4 3983/4885HPGD 2405/4885MAPK1 1556/4885 |
| US-20130190312-A1 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | WEE1, WEE2, NEK11 | CYP3A4 3983/4885HPGD 2405/4885MAPK1 1556/4885 |
| US-20150250794-A1 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | WEE1, WEE2, NEK11 | CYP3A4 3983/4885HPGD 2405/4885MAPK1 1556/4885 |
| US-10588909-B2 | Modulators of HEC1 activity and methods therefor | WEE1, WEE2, NEK11 | CYP3A4 3983/4885HPGD 2405/4885MAPK1 1556/4885 |
| US-11071736-B2 | Modulators of HEC1 activity and methods therefor | WEE1, WEE2, NEK11 | CYP3A4 3983/4885HPGD 2405/4885MAPK1 1556/4885 |
| US-20130082209-A1 | METAL COMPLEXES | MCOLN2, MCOLN1, AP1M1 | CYP3A4 2935/4885HPGD 3092/4885MAPK1 1656/4885 |
| US-20110230486-A1 | Modulators Of HEC1 Activity And Methods Therefor | WEE1, WEE2, NEK11 | CYP3A4 3834/4885HPGD 2722/4885MAPK1 1584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.